Compare Novo Nordisk A/S (NVO) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Ferrari NV — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Ferrari NV trades at $367.23 (market cap $65.48B). The key difference: Novo Nordisk A/S is far larger — about 3.4× Ferrari NV's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | RACE | |
|---|---|---|
Market Cap | $220.53B | $65.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $517.65 |
52-Week Low | $35.29 | $314.63 |
Enterprise Value | $239.49B | $66.69B |
Dividend Yield | 3.63% | 1.14% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
